Table 3 Baseline demographic and clinical characteristics of the patients who developed hypophosphatemia during the continuous veno-venous hemofiltration therapy period a
Characteristics | Patients (N= 521) | Survivors (n= 260) | Non-survivors (n= 261) | P |
|---|---|---|---|---|
Mean age (yr) | 60.34 | 57.97 | 62.71 | 0.002 |
Male sex (%) | 326 (62.6) | 163 (62.7) | 163 (62.5) | >0.999 |
Premorbidity (%) | 347 (66.6) | 155 (59.6) | 192 (73.6) | 0.001 |
Cardiovascular disease | 122 | 56 | 66 | |
Liver disease | 66 | 24 | 42 | |
Pulmonary disease | 25 | 12 | 13 | |
Cancer | 51 | 21 | 30 | |
Renal disease | 43 | 25 | 18 | |
Hematological disease | 22 | 7 | 15 | |
Other | 18 | 10 | 8 | |
Recent surgery (%) | 209 (40.1) | 104 (40.0) | 105 (40.2) | 0.929 |
Sepsis (%) | 304 (58.3) | 137 (52.7) | 167 (64.0) | 0.016 |
Chest | 177 (58.2) | 68 (49.6) | 109 (65.3) | |
Abdomen | 92 (30.3) | 51 (37.2) | 41 (24.6) | |
Bloodstream, including line-related infection | 25 (8.2) | 13 (9.5) | 12 (7.2) | |
Other or unknown source | 10 (3.3) | 5 (3.6) | 5 (3.0) | |
APACHE II score (mean) | 20.86 | 19.32 | 22.44 | <0.001 |
Length of mechanical ventilation (days) | 9.56 | 9.68 | 9.44 | 0.700 |
Prescribed dose of CVVH (mean in first 72 hours, ml/kg/h) | 50.78 | 50.12 | 51.43 | 0.272 |
Delivered dose of CVVH (median in first 72 hours, ml/kg/h) | 42.23 | 41.78 | 42.68 | 0.235 |
Therapeutic time of CVVH (days) | 9.49 | 9.60 | 9.37 | 0.710 |
Phosphate supplementation (%) | 355 (68.1) | 175 (67.3) | 180 (69.0) | 0.707 |
Ratio of CVVH therapy days with hypophosphatemia to total CVVH therapy days (mean) | 0.58 | 0.50 | 0.65 | <0.001 |
High ratiob (%) | 242 (46.4) | 96 (36.9) | 146 (55.9) | |
Low ratioc (%) | 279 (53.6) | 164 (63.1) | 115 (44.1) |